Parathyroid cancer: Diagnosis, treatment, and prognosis.

Marchand H*

Department of Pathology, University of pathology, France

Introduction

Parathyroid cancer, though rare compared to other types of endocrine malignancies, poses significant challenges due to its complex presentation and treatment requirements. This malignancy arises from the parathyroid glands, which are small endocrine organs located behind the thyroid gland in the neck. These glands are responsible for regulating calcium levels in the body through the secretion of Parathyroid Hormone (PTH). Understanding the diagnosis, treatment, and prognosis of parathyroid cancer is crucial for managing this aggressive disease effectively. The diagnosis of parathyroid cancer often begins with the recognition of symptoms associated with hyperparathyroidism, a condition characterized by excessive secretion of PTH leading to elevated calcium levels in the blood. Unlike benign parathyroid disorders, parathyroid cancer may present with more severe and persistent symptoms [1, 2].

Patients may experience symptoms such as significant hypercalcemia, which can lead to complications like bone pain, kidney stones, and neuropsychiatric disturbances such as depression or confusion. Additionally, the presence of a palpable neck mass or a rapidly growing tumor may raise suspicion of malignancy. Accurate diagnosis involves a combination of clinical evaluation, imaging studies, and histological examination. Initial diagnostic tests typically include serum calcium and PTH levels, which are often elevated in parathyroid cancer. High levels of calcium and PTH, especially if they are disproportionate to each other, can indicate a malignancy. Imaging studies such as neck ultrasound, sestamibi scans, and Computed Tomography (CT) scans play a critical role in locating the tumor and assessing its extent. These imaging modalities help in determining whether the cancer has metastasized to nearby structures or lymph nodes [3, 4].

However, imaging alone cannot definitively diagnose parathyroid cancer. The final diagnosis is usually confirmed through histological examination of tissue samples obtained via Fine Needle Aspiration (FNA) or surgical biopsy. Parathyroid cancer is distinguished from benign parathyroid tumors by its aggressive features, such as local invasion into surrounding tissues, vascular invasion, and higher mitotic activity. Immunohistochemical staining and molecular analyses may also be employed to differentiate parathyroid cancer from other conditions and to better understand the tumor's characteristics. Once diagnosed, the treatment of parathyroid cancer typically involves surgical intervention as the primary approach. Surgical management aims to remove the cancerous tissue entirely, and the extent of surgery depends on the tumor's size, location, and whether it has invaded adjacent structures. The surgical procedure usually involves parathyroidectomy, where the affected parathyroid gland and surrounding tissue are excised [5, 6].

In cases where the cancer has spread to nearby lymph nodes or other structures, a more extensive surgery including lymphadenectomy (removal of affected lymph nodes) or even partial thyroidectomy may be necessary. The role of adjuvant therapies in parathyroid cancer is more complex and less well-defined compared to other malignancies. Radiation therapy may be considered in cases where the cancer is not completely resectable or has spread to nearby tissues. Chemotherapy is generally not effective for parathyroid cancer due to the tumor’s poor response to standard chemotherapeutic agents. Instead, the focus often shifts to monitoring for recurrence and managing symptoms associated with hypercalcemia [7, 8].

The management of hypercalcemia is crucial in parathyroid cancer treatment. Elevated calcium levels can lead to a range of complications, including renal impairment, cardiovascular issues, and bone loss. Treatments such as intravenous bisphosphonates or denosumab may be used to control hypercalcemia and provide symptomatic relief. Additionally, addressing any skeletal complications through medications or supportive measures is essential to improving the patient's quality of life. Prognosis for parathyroid cancer varies based on several factors, including tumor size, stage at diagnosis, and response to treatment. Generally, parathyroid cancer has a poor prognosis compared to benign parathyroid disorders, with a higher risk of recurrence and metastasis. The overall survival rate for parathyroid cancer is lower than for many other endocrine cancers, partly due to the aggressive nature of the disease and the challenges in achieving complete tumor resection [9, 10].

Conclusion

In summary, parathyroid cancer is a rare but challenging malignancy that requires a multifaceted approach to diagnosis, treatment, and management. Accurate diagnosis involves a combination of biochemical tests, imaging studies, and histological examination. Surgical resection remains the primary treatment strategy, with additional measures taken to manage hypercalcemia and other complications. The prognosis

***Correspondence to:** Marchand H, Department of Pathology, University of pathology, France. E-mail: marchand678h@pu.fr

***Received:** 29-Jul-2024, Manuscript No. AAAGIM-24-145863; **Editor assigned:** 01-Aug-2024, PreQC No. AAAGIM-24-145863 (PQ); **Reviewed:** 14-Aug-2024, QC No. AAAGIM-24-145863; **Revised:** 19-Aug-2024, Manuscript No. AAAGIM-24-145863 (R); **Published:** 26-Aug-2024, DOI: 10.35841/aaagim-8.4.246*

***Citation:** Marchand H. Parathyroid cancer: Diagnosis, treatment, and prognosis. Arch Gen Intern Med. 2024;8(4):246.*

for parathyroid cancer is generally poor, emphasizing the importance of early detection and comprehensive management. As research continues, new insights and treatments may improve outcomes and offer hope for better management of this complex disease.

References

1. Rodrigo JP, Hernandez-Prera JC, Randolph GW, et al. Parathyroid cancer: An update. Cancer Treat Rev. 2020;86:102012.
2. Thwin M, MClinSci RM. Parathyroid Cancer. Surg Oncol Clin N Am. 2023;32(2):271-8.
3. Davies MP, Evans TW, Tahir F, et al. Parathyroid cancer: a systematic review of diagnostic biomarkers. Surgeon. 2021;19(6):e536-48.
4. Simonds WF. Genetics of hyperparathyroidism, including parathyroid cancer. Endocrinology and Metabolism Clinics. 2017;46(2):405-18.
5. Stark J, Toke J, Huszty G, et al. Parathyroid cancer with MTOR gene mutation: Case report and review of the literature. Ann Endocrinol. 2023;84(6): 761-763.
6. Goldner E, Fingeret A. Parathyroid carcinoma: a national cancer database analysis. J Surg Res. 2023;281:57-62.
7. Splíchalová E, Holý R, Traboulsi E, et al. Nonfunctional parathyroid cancer a case report. Rozhl Chir. 2021;100(3):133-7.
8. Radu P, Garofil D, Tigora A, et al. Parathyroid Cancer—A Rare Finding during Parathyroidectomy in High Volume Surgery Centre. Medicina. 2023;59(3):448.
9. Tsai WH, Zeng YH, Lee CC, et al. Mortality factors in recurrent parathyroid cancer: a pooled analysis. J Bone Miner Metab. 2022;40(3):508-17.
10. Falchetti A. New Perspective on the Genetic Dissection Underlying the Development of Parathyroid Cancer. J Clin Endocrinol Metab. 2023;108(12):e1751-2.

Citation: *Marchand H. Parathyroid cancer: Diagnosis, treatment, and prognosis. Arch Gen Intern Med. 2024;8(4):246.*